Heron Therapeutics, Inc. (HRTX) Receives “Buy” Rating from Noble Financial
Several other analysts have also commented on HRTX. BidaskClub lowered shares of Heron Therapeutics from a hold rating to a sell rating in a research note on Friday, August 18th. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a buy rating in a research note on Friday, August 18th. Zacks Investment Research raised shares of Heron Therapeutics from a sell rating to a hold rating in a research note on Wednesday, November 8th. Mizuho reissued a buy rating and set a $28.00 target price on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Finally, Jefferies Group LLC reissued a buy rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $28.36.
Shares of Heron Therapeutics (NASDAQ HRTX) traded down $1.00 during trading hours on Friday, hitting $16.35. 2,357,100 shares of the stock were exchanged, compared to its average volume of 817,824. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $20.85. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The business had revenue of $8.57 million during the quarter, compared to analyst estimates of $8.12 million. equities analysts forecast that Heron Therapeutics will post -3.42 earnings per share for the current year.
Several large investors have recently modified their holdings of HRTX. Janus Henderson Group PLC purchased a new stake in shares of Heron Therapeutics in the 2nd quarter valued at approximately $78,134,000. Vanguard Group Inc. lifted its position in shares of Heron Therapeutics by 40.2% in the 1st quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock valued at $28,127,000 after acquiring an additional 537,563 shares in the last quarter. State Street Corp lifted its position in shares of Heron Therapeutics by 30.7% in the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock valued at $26,822,000 after acquiring an additional 420,113 shares in the last quarter. Chartwell Investment Partners LLC purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at approximately $2,340,000. Finally, Credit Suisse AG lifted its position in shares of Heron Therapeutics by 329.8% in the 1st quarter. Credit Suisse AG now owns 144,061 shares of the biotechnology company’s stock valued at $2,161,000 after acquiring an additional 110,539 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.